Evidence map›Paper›PMID 41963512›Full record

ArticleScientific reports2026

Metabolic and functional pathways of gut microbiota in patients with gastric cancer.

Ryo Matoba, Hiroshi Iijima, Yasuhiro Sakamoto, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masaki Aizawa, Jin Matsuyama, Masazumi Takahashi and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Ryo MatobaDNA Chip Research Inc., Kawasaki, Japan. matoba@dna-chip.co.jp.
Hiroshi IijimaDNA Chip Research Inc., Kawasaki, Japan.
Yasuhiro SakamotoDepartment of Medical Oncology, Osaki Citizen Hospital, Osaki, Japan.
Ryohei KawabataDepartment of Surgery, Sakai City Medical Center, Sakai, Japan.
Atsushi IshiguroDepartment of Medical Oncology, Teine Keijinkai Hospital, Sapporo, Japan.
Yusuke AkamaruDepartment of Surgery, Osaka Rosai Hospital, Sakai, Japan.
Yosuke KitoDepartment of Medical Oncology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
Masaki AizawaDepartment of Gastroenterological Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Jin MatsuyamaDepartment of Gastroenterological Surgery, Higashiosaka City Medical Center, Higashi-Osaka, Japan.
Masazumi TakahashiDivision of Gastroenterological Surgery, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
Akitaka MakiyamaCancer Center, Gifu University Hospital, Gifu, Japan.
Takahisa SuzukiDepartment of Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Masahiro TsudaDepartment of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan.
Hisateru YasuiDeparment of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
Jun HiharaDepartment of Surgery, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Japan.
Hiroyuki OkudaDepartment of Medical Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan.
Junji KawadaDepartment of Surgery, Yao Municipal Hospital, Yao, Japan.
Takashi YoshiokaDepartment of Medical Oncology, Yamagata University Hospital, Yamagata, Japan.
Hisato KawakamiDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Takako Eguchi NakajimaDepartment of Early Clinical Development, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kei MuroDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Wataru IchikawaDivision of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan.
Masashi FujiiJapan Clinical Cancer Research Organization (JACCRO), Tokyo, Japan.
Yu SunakawaDepartment of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan. y.sunakawa@marianna-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We analysed the differences in bacterial composition between 475 Japanese patients with advanced gastric cancer (median age, 70 years; median BMI 20.0) and 106 healthy individuals using a comprehensive metagenome shotgun analysis. Among the patients with advanced gastric cancer, 71% were male, 37% had relapsed, and 55.5% previously underwent gastrectomy. Bifidobacterium, Anaerostipes, and Parabacteroides were predominant in healthy individuals, whereas Streptococcus, Lactobacillus, and Odoribacter were predominant in patients with advanced gastric cancer. Additionally, Kyoto Encyclopedia of Genes and Genomes pathway analysis showed that butanoate and pyruvate metabolism was enriched in healthy individuals, whereas factors, such as ABC transporters and ribosomes, were enriched in patients with advanced gastric cancer. Cluster analysis broadly classified patients with advanced gastric cancer and healthy individuals into two clusters; however, clustering using pathway data more clearly classified patients with advanced gastric cancer and healthy individuals than clustering using flora analysis. Moreover, healthy individuals showed higher bacterial flora diversity than those with advanced gastric cancer. Although the dataset we used was limited and may be difficult to generalise, we identified some molecular characteristics and functional pathways of the microbial genera within the intestines of patients with advanced gastric cancer.

Indexed as

Gastrointestinal MicrobiomeMetabolic Networks and PathwaysStomach NeoplasmsAgedAged, 80 and overBacteriaFemaleHumansMaleMetagenomeMetagenomicsMiddle AgedFaecal microbiomeFunctional pathwayGastric cancerMetagenomic shotgunMolecular diagnosis

Identifiers

PMID41963512
PMCPMC13230625

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.